Roth Capital Resumes Dare Bioscience (DARE) at Buy, 'We believe that the risk-reward is favorable'
Tweet Send to a Friend
(Updated - January 5, 2023 10:07 AM EST)
Roth Capital analyst Kumaraguru Raja resumes coverage on Dare Bioscience (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Roth Capital analyst Kumaraguru Raja resumes coverage on Dare Bioscience (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
